Skip to main navigation
Pharvaris N.V logo
Main Menu

Header Nav

  • Our science
  • our pipeline
  • disease focus: HAE
  • HAE community
  • clinical trials
  • About us
    • about us
    • join us
    • Contact
  • Investors
Investor Menu

IR Nav

  • Overview
  • News & Events
    • News Releases
    • Events & Presentations
    • Publications
  • Financials
    • SEC Filings
  • Stock
    • Stock Performance
    • Analyst Coverage
  • Corporate Governance
    • Governance Documents
    • Management Team
    • Board of Directors
    • Committee Composition
  • Resources
    • FAQ
    • Contact Us
    • Email Alerts

Event Details

Breadcrumb

Home / Investor Relations / Events & Presentations / ACAAI Annual Scientific Meeting 2022

ACAAI Annual Scientific Meeting 2022

Nov 10 - Nov 14, 2022

Supporting Materials

Pharvaris to Present PHVS416 and PHVS719 Clinical Data for Treatment of HAE at the ACAAI Annual Scientific Meeting 2022
Development of PHVS719: an Oral Extended-Release Bradykinin B2 Receptor Antagonist to Prevent Hereditary Angioedema Attacks 818.4 KB
Pharmacokinetics of PHVS719, extended-release tablet formulation of PHA121, a first-in-class oral human bradykinin B2-receptor antagonist 937.4 KB

Toolkit

Print Page
Print Page
Email Alerts
Email Alerts
IR Contacts
IR Contacts

Footer Links

Privacy     Cookie notice     Terms of Use

Social Links

  • Pharvaris 2020 - © All rights reserved